GLP-1 receptor agonists in NAFLD

J-M Petit; B Vergès

doi:10.1016/S1262-3636(17)30070-8

GLP-1 receptor agonists in NAFLD

Diabetes Metab. 2017 Apr:43 Suppl 1:2S28-2S33. doi: 10.1016/S1262-3636(17)30070-8.

Authors

J-M Petit¹, B Vergès²

Affiliations

¹ Université de Bourgogne, Centre de Recherche INSERM LNC-UMR1231; Service de Diabétologie et Endocrinologie, CHU François Mitterand, BP 77908, Dijon cedex 21079, France. Electronic address: [email protected].
² Université de Bourgogne, Centre de Recherche INSERM LNC-UMR1231; Service de Diabétologie et Endocrinologie, CHU François Mitterand, BP 77908, Dijon cedex 21079, France.

PMID: 28431668
DOI: 10.1016/S1262-3636(17)30070-8

Abstract

Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.

Keywords: Fibrosis; GLP-1 receptor agonists; Non-alcoholic fatty liver disease; Steatosis; type 2 diabetes.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Glucagon-Like Peptide-1 Receptor Agonists*
Humans
Hypoglycemic Agents / therapeutic use*
Non-alcoholic Fatty Liver Disease / complications
Non-alcoholic Fatty Liver Disease / drug therapy*
Treatment Outcome

Substances

Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor Agonists